InsuranceTom said:Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…
I read this differently from InsuranceTom, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.
Dr.EndoIndy said:Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
Dr.ObesityLA said:The affordability discussion here usually stops at individual tactics.
Dr.ObesityLA said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.